FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Botanix Pharmaceuticals Limited Stock AnalysisComprehensive stock analysis for Botanix Pharmaceuticals Limited (BXPHF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBXPHF
BXPHF
Botanix Pharmaceuticals Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BXPHF
Home🔹Stocks🔹Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited

BXPHF•OTC

Botanix Pharmaceuticals Limited

BXPHF•OTC
Market cap
$88.95M
Sentiment

Your view on BXPHF

Mkt Cap
$88.95M
Sentiment
Your view
BXPHF
Botanix Pharmaceuticals Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BXPHF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Botanix Pharmaceuticals Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Howie McKibbon
Headquarters
D2, 661 Newcastle Street, Leederville, WA, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Howie McKibbon
Headquarters
D2, 661 Newcastle Street, Leederville, WA, AU
Description

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News